Skip to main content
PLOS One logoLink to PLOS One
. 2021 Sep 7;16(9):e0256657. doi: 10.1371/journal.pone.0256657

Microbiota composition and mucosal immunity in patients with asymptomatic diverticulosis and controls

Tessel M van Rossen 1,*,#, Rogier E Ooijevaar 2,#, Johan Ph Kuyvenhoven 3, Anat Eck 1, Herman Bril 4, René Buijsman 5, Marja A Boermeester 6, Hein B A C Stockmann 7, Niels de Korte 7,, Andries E Budding 8,
Editor: Christopher Staley9
PMCID: PMC8423250  PMID: 34492052

Abstract

Introduction

The etiology of diverticulosis is still poorly understood. However, in patients with diverticulitis, markers of mucosal inflammation and microbiota alterations have been found. The aim of this study was to evaluate potential differences of the gut microbiota composition and mucosal immunity between patients with asymptomatic diverticulosis and controls.

Methods

We performed a prospective study on patients who underwent routine colonoscopy for causes not related to diverticular disease or inflammatory bowel disease. Participants were grouped based on the presence or absence of diverticula. Mucosal biopsies were obtained from the sigmoid and transverse colon. Microbiota composition was analyzed with IS-pro, a 16S-23S based bacterial profiling technique. To predict if patients belonged to the asymptomatic diverticulosis or control group a partial least squares discriminant analysis (PLS-DA) regression model was used. Inflammation was assessed by neutrophil and lymphocyte counts within the taken biopsies.

Results

Forty-three patients were enrolled. Intestinal microbiota profiles were highly similar within individuals for all phyla. Between individuals, microbiota profiles differed substantially but regardless of the presence (n = 19) of absence (n = 24) of diverticula. Microbiota diversity in both sigmoid and transverse colon was similar in all participants. We were not able to differentiate between diverticulosis patients and controls with a PLS-DA model. Mucosal lymphocyte counts were comparable among both groups; no neutrophils were detected in any of the studied biopsies.

Conclusions

Microbiota composition and inflammatory markers were comparable among asymptomatic diverticulosis patients and controls. This suggests that the gut microbiota and mucosal inflammation do not play a major role in the pathogenesis of diverticula formation.

Introduction

Diverticulosis is a common gastrointestinal disorder that is usually asymptomatic (asymptomatic diverticulosis; AD). Since it is often found incidentally during routine endoscopic or radiological exam, a true incidence and prevalence of diverticulosis is lacking. It is estimated that roughly 67% of the adult population will develop diverticulosis during their lifespan [1]. Several risk factors have been proposed such as a low fiber diet, smoking, obesity, male sex, aging, and lack of physical exercise [2]. The etiology of diverticulosis is still poorly understood. Genetics and increased colonic intraluminal pressure appear to play an important role [3]. Given the gut microbiota composition is influenced by the aforementioned risk factors, the gut microbiota could be implicated in the pathophysiology of diverticulosis.

Diverticulitis or diverticular disease occurs when a diverticulum becomes inflamed. Clinical symptoms such as abdominal tenderness, constipation or diarrhea, fever and pain can occur. It is still poorly understood what drives a diverticulum to become inflamed. A common but unproven hypothesis states that obstruction and microtrauma in a diverticulum, leads to perforation and subsequent infection. Based on this hypothesis the use of antibiotics for diverticulitis is common practice [2]. However, a recent study suggests that antibiotic treatment may not improve the outcome in diverticulitis [4].

The gut microbiota composition and function has been implicated in health and several diseases, such as Clostridioides difficile infection, inflammatory bowel disease, and irritable bowel syndrome [5]. Several studies have shown a different composition in gut microbiota compared to controls in (uncomplicated) diverticulitis [1, 6]. However, there is a paucity of microbiota data in patients suffering from AD. The gut microbiota could be implicated in the pathophysiology of diverticulosis and subsequent diverticulitis. With the recent advances in molecular-techniques it is now possible to map the microbiota from different bodily surfaces such as the bowel mucosa. The interspace region (IS)-pro technique, a 16S-23S based bacterial profiling technique is validated for use in the intestinal microbiota [7].

The etiology of diverticulosis and subsequent diverticulitis may very well be multifactorial including changes in microbiota composition and function. The aim of this study is to characterize mucosal inflammation and differences in colonic mucosal microbiota in individuals with diverticulosis as compared to a control population. This can contribute to further unraveling the etiology of diverticulosis and guide future research on treatment and prevention.

Materials and methods

Study design

A prospective single-center study was performed in patients undergoing routine follow-up colonoscopy for causes not related to diverticulitis or inflammatory bowel disease. The study was conducted on a convenience sample size. All patients underwent routine bowel lavage for colonoscopy. When patients enrolled into our study, colonoscopy was performed by a single gastroenterologist. Participants were enrolled into either the asymptomatic diverticulosis group (AD group) or the no diverticulosis group (control group), based on the findings during colonoscopy. When diverticula were encountered during colonoscopy five biopsies were taken from the mucosa surrounding the diverticula in the sigmoid colon and five biopsies were taken from the transverse colon as control biopsies. When no diverticula were encountered during colonoscopy, five biopsies were obtained from the sigmoid and transverse colon at random.

Patients

Patients aged 18 years or older undergoing a routine colonoscopy were eligible for recruitment. Exclusion criteria were: suspicion of diverticular related complaints, proven history of symptomatic diverticulitis, history of inflammatory bowel disease or the use of anticoagulants or platelet aggregate inhibitors unless stopped one week prior to colonoscopy. Written informed consent was obtained from all subjects prior to participation. Study approval was provided by the local research ethics committee, Medisch-Ethische Toetsingscommissie (METC) Noord-Holland. All research was performed in accordance with relevant guidelines and regulations.

DNA isolation and amplification

After harvesting the colonic biopsies were washed in phosphate buffered saline to remove residual fecal material and non-adherent bacteria. Subsequently, biopsies were placed in Eppendorf tubes and snap frozen in liquid nitrogen and stored at -20°C. After thawing of the samples, one ml of NucliSENS lysisbuffer, containing guanidine thiocyanate, was added to each Eppendorf tube and shaken at 1400rpm (Thermomixer comfort, Eppendorf, Hamburg, Germany) for five minutes. Afterwards, all samples were centrifuged for four minutes at 12.000g and added to the easyMag container for total DNA extraction with the NucliSENS easyMag automated DNA isolation machine (Biomérieux, Marcy l’Etoile, France). We have described DNA isolation in detail previously [7].

Microbiota and data analysis

Amplification of 16S-23S IS-regions was performed with the IS-pro microbiota assay (inBiome B.V., Amsterdam, the Netherlands). IS-profiling was done as described previously [7]. All data were pre-processed with the IS-pro proprietary software suite (inBiome B.V., Amsterdam, the Netherlands). This process resulted in peak profiles with the length of each peak, measured in nucleotides, representing a IS fragment corresponding to a specific bacterial species. The intensity of each peak, measured in relative fluorescence units (RFU), reflected the quantity of PCR product and corresponded to the abundance of that species. Finally, phylum-specific fluorescent labels categorized peaks into three phylogenetic groups: Proteobacteria, Bacteroidetes or Firmicutes/Actinobacteria/Fusobacteria/Verrucomicrobia (FAFV). All intensities were log2 transformed. Log2 transformation of complex profiles compacts the range of variation in peak heights, reducing the dominance of high peaks and including less abundant species of the microbiota in downstream analyses. This results in improved consistency of estimated correlation coefficient, lower impact of inter-run variation and improved detection of less prominent species. This conversion was used in all downstream analyses.

Cosine distance and diversity analysis

To analyze similarities between samples, a cosine distance analysis and a diversity analysis was performed. Cosine distance analysis was performed per phylum and for total microbiota composition at species level within individuals (sigmoid vs transverse colon biopsies) and between individuals (sigmoid vs sigmoid colon) for asymptomatic diverticulosis patients and controls. Diversity was calculated both per phylum and for the overall microbial composition (by pooling all phyla together). Within-sample diversity was calculated as the Shannon index [8]. Dissimilarities between samples, or between-sample diversity, was represented in a dissimilarity matrix that was built using the cosine distance measure [9]. Diversity analysis was performed using the vegan software package in R.

Partial least squares discriminant analysis (PLS-DA)

A partial least squares discriminant analysis (PLS-DA) regression model was used for the prediction of clinical status of samples; i.e. whether it belonged to a diverticulosis patient or to a control subject [10]. The PLS-DA model was constructed on the basis of four different datasets: one for each of the three separate phylum groups and one for the overall microbial composition by pooling all phyla. Only the top 25% most variable predictors were considered in the analysis. PLS-DA model validation was carried out by a 10-fold cross validation procedure. The PLS-DA was described in extenso in a previous study performed by us [11]. PLS-DA analysis was performed using the DiscriMiner package in R (version 2.15.2). All data visualizations were performed with the Spotfire software 10 package (TIBCO, Palo Alto, CA, USA).

Clustered heat map

For a global analysis of all versus all samples, we generated a clustered heat map. First, a correlation matrix was generated by means of cosine correlation, then clustering was done with the unweighted pair group method with arithmetic mean (UPGMA). The heat map was created with the Spotfire 10 software package (TIBCO, Palo Alto, CA, USA, https://www.tibco.com/products/tibco-spotfire).

Histology

The presence of inflammatory changes was assessed as previously described by performing a neutrophil and lymphocyte count on 10 different colonic fields at 40 x magnification [12]. Hematoxylin-eosin staining was performed. Lymphocytes were identified with anti-CD3 antibodies (ready to use rabbit anti human polyclonal antibodies, DAKO, Copenhagen, Denmark), for neutrophils anti-CD15 antibodies (ready to use mouse anti human monoclonal antibodies, DAKO, Copenhagen, Denmark) were used. The number of lymphocytes and neutrophils were scored both at the bottom of the crypts and in the crypts as a whole. For histological evaluation the means of lymphocyte and neutrophils infiltrate were compared using the Mann-Whitney test. A P value of <0.05 was considered statistically significant.

Results

Patient characteristics

A total of 43 patients were enrolled of which 19 had AD and 24 had no diverticulosis. Patient characteristics and indications for colonoscopy are shown in Table 1. The asymptomatic diverticulosis group consisted of more males than the control group; however, this difference was not statistically significant (74 vs. 38%, p = 0.063). Patients in the AD group were significantly older than patients in the control group (mean age 66.0 vs. 56.4 years, p = <0.001). Six out of 19 AD patients were smokers, compared to 3/24 controls, and alcohol consumption was slightly higher in the AD group compared to the control group. None of the patients received antibiotics via the hospital prior to colonoscopy. The number of patients with specific comorbidities was similar in the two groups, except that gastro-intestinal disorders and malignancies (but not colon cancer) were more frequent in the control group compared to the AD group. Gastro-intestinal comorbidity in the control group concerned esophagitis (n = 2), aspecific colitis (n = 1) and irritable bowel syndrome (n = 1).

Table 1. Patient characteristics.

e.c.i.: e causa ignota.

Characteristic Asymptomatic diverticulosis group Control group
N = 19 N = 24
Male gender 14 (74%) 9 (38%)
Age in years 66.0 (62.7–69.3) 56.4 (52.7–60.2)
Smoking 6 3
Alcohol use (standard volumes/week) 5.9 (2.1–9.6) 4.1 (1.4–6.8)
Laxative use 3 1
Antibiotic use 0 0
Comorbidity:
    Cardiovascular 9 8
        Hypertension 5 6
    Pulmonary 1 3
    Renal 0 0
    Gastro-intestinal 0 4
    Liver disease 0 1
    Malignancy 2 8
        Colon cancer 0 0
    Rheumatologic 3 1
    Neurologic 7 7
    Diabetes mellitus 2 4
    Immunocompromised 0 0
Indication for colonoscopy:
    Hematochezia 1 3
    Change in bowel habit 2 2
    Anemia e.c.i. 0 1
    Obstipation 0 3
    Screening and follow up colorectal carcinoma 2 4
    Follow up after polypectomy 13 9
    Other 1 2

Intestinal microbiota analysis

The Firmicutes to Bacteroidetes ratio is commonly used to describe the gut microbiota composition. A higher Firmicutes/Bacteroidetes ratio is associated with dysbiosis [13, 14]. Therefore, we compared the relative abundance of these phyla between the AD and control group. In the AD group we found a Firmicutes/Bacteroidetes ratio of 38%/62% (variance 0.018). Almost identical proportions were found in the control group (Firmicutes 37%/Bacteroidetes 63%, variance 0.021) with no statistical differences between the two groups (p = 0.69, Students T-test). Also, the total load of bacteria of the Proteobacteria phylum was similar between diverticulosis patients and controls (p = 0.56, Students T-test).

Cosine distance

Cosine distance analysis was performed to compare microbiota compositions in participants with AD and controls. To detect potential diverticula-related differences in microbiota composition, we assessed cosine distances of bacterial profiles of the sigmoid and transverse colon within individuals with and without AD. We observed slight location-related differences in both groups–most clearly for the Proteobacteria phylum–but the range of these intra-individual differences was comparable in the AD and control group. Secondly, we assessed if the microbiota composition differed between participants with and without AD. Therefore, we performed an inter-individual comparison of all diverticular biopsies in the AD group and an inter-individual comparison of all sigmoid colon biopsies in the control group (Fig 1). Overall, correlations of microbiota profiles between patients were low. The variation of bacterial profiles between individuals was similar in the AD and control group. If there was a specific diverticulosis signature, higher similarity within the AD group than within the control group would be expected.

Fig 1. Cosine distance analysis of intestinal microbiota profiles within and between individuals.

Fig 1

Microbiota profiles are highly similar within individuals for all phyla, regardless of disease status (C = control, AD = asymptomatic diverticulosis). Between individuals microbiota profiles are dissimilar. FAFV: Firmicutes/Actinobacteria/Fusobacteria/Verrucomicrobia.

Diversity

Microbiota diversity of all biopsies was analyzed by calculating the Shannon diversity index (Fig 2). The highest diversity was detected in the Bacteroidetes phylum. No differences were observed in the phylum-specific and all phyla pooled diversity indices of transverse and sigmoid colon biopsies. Furthermore, bacterial diversity was similar for individuals with and without AD.

Fig 2. Diversity analysis of intestinal microbiota per phylum.

Fig 2

Diversity is highest for Bacteroidetes, followed by FAFV group and Proteobacteria. Diversity is not different in sigmoid (S) and transverse (T) colon or for asymptomatic diverticulosis (AD) patients or controls. FAFV: Firmicutes/Actinobacteria/Fusobacteria/Verrucomicrobia.

Partial least squares discriminant analysis (PLS-DA)

A PLS-DA model was constructed to predict whether a biopsy belonged to an individual with AD or a control subject, based on the association between specific bacterial species and the presence of AD. We developed a model that could distinguish between individuals with and without AD with an accuracy of 74%. However, the model showed poor performance when performing 10-fold cross-validation (Fig 3). This suggests that the biopsies did not contain any bacterial species specific for the presence or absence of diverticula.

Fig 3. Three dimensional PLS-DA scores plot of microbiota samples based on the most discriminative PLS components.

Fig 3

It can be clearly seen that there is no separation, suggesting the absence of discriminative species for either state (asymptomatic diverticulosis, AD, or controls).

Clustered heat map

We performed a cluster analysis based on microbiota profile similarity between single biopsies. A heat map and dendrogram were constructed including all samples of the AD group and controls (Fig 4). Most resulting ‘clusters’ consisted of biopsy pairs containing a transverse colon and sigmoid colon biopsy of the same patient. This indicates that the intra-individual microbiota profiles showed a higher correlation than inter-individual microbiota profiles. Some biopsies clustered with a biopsy from another individual, but this was not related to the presence or absence of diverticula.

Fig 4. Clustered heat map of all mucosal biopsy samples.

Fig 4

Each column represents a sample from either sigmoid (S) or transverse (T) colon. Each band represents a IS fragment corresponding to a specific bacterial species, the intensity to its abundance, the color to its phylum group. Generally, microbiota of the sigmoid colon shows highest correlation to the microbiota of the transverse colon of the same individual (all blue squares). Sometimes, correlation is stronger to a sample from another individual (yellow squares). However, no clear pattern can be seen here: samples from the asymptomatic diverticulosis (AD) group have a similar likelihood to having a low intra-individual correlation as control samples. Thus, random variation seems to be a more likely explanation here than an underlying biological phenomenon. Finally, there is no evident clustering of controls or AD individuals. FAFV: Firmicutes/Actinobacteria/Fusobacteria/Verrucomicrobia. The heat map was created with the Spotfire 10 software package (TIBCO, Palo Alto, CA, USA, https://www.tibco.com/products/tibco-spotfire).

Neutrophil and lymphocyte counts

On examination of the biopsies, none contained influx of neutrophils. Furthermore, we observed no difference in mean lymphocyte counts between both groups when we compared the lymphocyte counts, in the bottom of the crypts, or in the crypts as a whole. This was true for the sigmoid colon as well as the transverse colon (Table 2).

Table 2. Mean lymphocyte counts.

Location Asymptomatic diverticulosis group Control group P value
N = 19 N = 24
Transverse colon, bottom of crypt 1.86 2.22 0,849
Transverse colon, whole crypt 9.56 8.39 0,261
Sigmoid colon, bottom of crypt 1.56 1.8 0,754
Sigmoid colon, whole crypt 6.95 7.12 0,765

Discussion

In our study, intestinal microbiota profiles were highly similar within individuals for all phyla. Inter- individually, microbiota profiles differed substantially but without a clear association with the presence or absence of diverticula. Microbiota diversity in both sigmoid and transverse colon mucosal biopsies was comparable between both groups. We were not able to differentiate between the AD group and controls with a PLS-DA model based on the participants’ microbiota composition or clustered heat map analysis. Mucosal lymphocyte counts were comparable between both groups. No neutrophils were detected in any of the studied biopsies. Our results suggest that compositional microbiota alterations and inflammation do not play a substantial role in the pathophysiology of diverticulosis. Our study did confirm the age-association with diverticulosis. The group of patients with diverticula was substantially older when compared to those without.

While AD by itself has no treatment currently, progression to symptomatic diverticulitis can lead to extensive surgery. Recently, there has been a paradigm shift pertaining to the etiology of diverticulitis. The traditional hypothesis that diverticulitis is caused by a fecalith obstruction of a diverticulum is replaced by the theory that diverticulitis has a multifactorial pathogenesis with an important role for the gut microbiota [9, 15]. We demonstrated previously that the gut microbiota in patients with diverticulitis differed from that of controls [9]. For diagnostic and possible treatment purposes, it would be interesting to see whether these changes in microbiota composition are also present in individuals before they develop diverticulitis. Moreover, if diverticulitis or development of diverticulosis could be predicted using microbiota analysis, this may result in more timely treatment and prevention of complications, and could allow for specific microbiota modulating therapies.

Few articles have been published on the gut microbiota composition in patients with AD. The largest study to date was conducted by Jones et al. [16]. They performed 16S-sequencing on mucosal samples of patients with AD and controls, and found weak associations between decreased relative abundance of Proteobacteria and Comamonadaceae and the presence of diverticula. They concluded that the mucosal adherent microbiota is unlikely to play a substantial role in development of diverticulosis, in accordance with our findings.

Tursi et al. used RT-PCR to detect specific microorganisms in fecal samples of patients with diverticulosis [17]. They reported no significant difference in total number of bacteria or in abundance of specific bacterial groups between patients with AD, patients with symptomatic uncomplicated diverticular disease (SUDD) and controls. Interestingly, Akkermansia muciniphila species was more abundant in patients with AD and SUDD than in controls. This is a remarkable finding, given A. muciniphila is considered a healthy gut commensal which is depleted in many inflammatory disorders [18]. Different to our study, fecal samples were analyzed using RT-PCR for microbiota composition, representing the luminal gut microbiota. This yields less information pertaining to the diverticular sites. Furthermore RT-PCR only allows for a limited number bacteria to be analyzed compared to 16S-based techniques.

Another study on microbiota alterations in diverticulosis was conducted by Barbara et al [6]. For microbiota analysis, 16S-sequencing was performed on both mucosal biopsies and stool samples. In concordance with our results, microbiota composition in colonic biopsies did not differ between patients with AD and controls. When AD and SUDD groups were combined and compared with controls, Barbara et al. observed a significant lower abundance of Enterobacteriaceae and a trend to higher abundance of Bacteroides/Prevotella in the combined AD/SUDD group. In feces, patients with SUDD had a significant decreased abundance of members of Clostridium cluster IX, Fusobacteriae and Lactobacillaceae compared to patients with AD.

Besides differences in microbiota composition, Barbara et al. focused on inflammatory markers in patients with diverticula. Identical to our results, they observed no difference in (T-)lymphocytes between patients with AD and patients without diverticula. Furthermore, two larger studies (n = 254 and n = 619) reported no association between colonic diverticula and numerous markers of mucosal and serological inflammation [19, 20]. In contrast, Barbara et al. observed a significantly higher macrophage count in patients with AD and SUDD compared with controls, suggesting there is some inflammatory process implicated in the pathophysiology of diverticulosis.

One of the strengths of our study is the use of mucosal biopsies for microbiota analysis instead of fecal samples. Because biopsies were collected from both the sigmoid and the transverse colon, we were able to assess potential local, diverticular related differences in microbiota composition. Another strength is that we used PLS-DA analysis, a sensitive technique in identifying biomarkers associated with disease state in complex data. Therefore, the lack of discriminating species found with PLS-DA does suggests the absence of a discriminative biomarker in this dataset.

Our study is hampered by several drawbacks. Firstly, our sample size is small and AD patients and controls were not matched by age. As AD is commonly found with increasing age, our study is not powered to find subtle, age-dependent differences in microbiota composition. Age is generally considered one of the main determinants of intestinal microbiota composition, however this begins to be relevant after the age of 70–75 years old, especially if no significant comorbidities or disability exist [21, 22]. This is in line with our finding that although the AD group was significantly older than the control group (66 vs 56 years respectively), the microbiota composition did not differ between the two groups. We only had limited availability to patient demographics. Several other factors such as diet can influence microbiota composition for which should be corrected [23].

Furthermore, using next-generation sequencing could reveal more subtle differences in microbiota composition in patients with- and without diverticula. 16S rRNA gene sequencing is currently seen as the gold standard for the profiling of the microbiome. However, for routine diagnostics or rapid processing of (small) sample batches, 16S rRNA gene sequencing is not well suited due to costs and time-consumption, creating space for other techniques. The IS-pro technique was developed with the goals of cost-effectiveness and simplicity in mind. Furthermore, analysis of proteomics and metabolomics could possibly reveal functional changes in the gut microbiota within an unchanged compositional microbiota. Comparison of the luminal microbiota (via fecal sample analysis) with mucosal biopsies could provide more insight in a possible interplay between these fractions of the gut microbiota. Another limitation is that microbiota analysis was performed on mucosal samples after bowel lavage, which has been shown to impact intestinal microbiota composition [24]. However, it is not possible to conduct a colonoscopy in a patient without prior bowel lavage. Another option might be to use rectal swabs or feces to verify whether the composition of the mucosal and fecal microbiota was consistent. Furthermore, collection of rectal swabs or feces is more practical and patient-friendly, although these methods have their own disadvantages as described before [24, 25]. Lastly, we only obtained lymphocyte and neutrophil counts as markers for inflammation. An assessment of other immune cells such as macrophages, or cytokines in our data set could provide a more detailed view of the mucosal immunity in patients with AD and should be evaluated in future studies.

In conclusion, microbiota composition and inflammatory markers were comparable among patients with asymptomatic diverticulosis and controls. This suggests that the gut microbiota composition and mucosal inflammation do not play a major role in the pathogenesis of diverticula formation. Whether microbiota and mucosal inflammatory changes as have been observed in diverticulitis are cause or sequelae of the disease remains unclear and merits further investigation.

Supporting information

S1 File. Patient characteristics.

(XLSX)

S2 File. Microbiota data.

(XLSX)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

Anat Eck was supported by The Netherlands Organisation for Health Research and Development (ZonMw), grant number 95103009. inBiome B.V. and ZonMw supported in the form of salaries for authors [AEB, AE], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.

References

  • 1.Tursi A. Diverticulosis today: unfashionable and still under-researched. Ther Adv Gastroenter. 2016;9(2):213–28. doi: 10.1177/1756283X15621228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Strate LL, Morris AM. Epidemiology, Pathophysiology, and Treatment of Diverticulitis. Gastroenterology. 2019;156(5):1282–98 e1. doi: 10.1053/j.gastro.2018.12.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tursi A, Scarpignato C, Strate LL, Lanas A, Kruis W, Lahat A, et al. Colonic diverticular disease. Nat Rev Dis Primers. 2020;6(1):20. doi: 10.1038/s41572-020-0153-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Daniels L, Unlu C, de Korte N, van Dieren S, Stockmann HB, Vrouenraets BC, et al. Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis. Br J Surg. 2017;104(1):52–61. doi: 10.1002/bjs.10309 [DOI] [PubMed] [Google Scholar]
  • 5.Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical Application and Potential of Fecal Microbiota Transplantation. Annu Rev Med. 2019;70:335–51. doi: 10.1146/annurev-med-111717-122956 [DOI] [PubMed] [Google Scholar]
  • 6.Barbara G, Scaioli E, Barbaro MR, Biagi E, Laghi L, Cremon C, et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut. 2017;66(7):1252–61. doi: 10.1136/gutjnl-2016-312377 [DOI] [PubMed] [Google Scholar]
  • 7.Budding AE, Grasman ME, Lin F, Bogaards JA, Soeltan-Kaersenhout DJ, Vandenbroucke-Grauls CM, et al. IS-pro: high-throughput molecular fingerprinting of the intestinal microbiota. FASEB J. 2010;24(11):4556–64. doi: 10.1096/fj.10-156190 [DOI] [PubMed] [Google Scholar]
  • 8.Haegeman B, Hamelin J, Moriarty J, Neal P, Dushoff J, Weitz JS. Robust estimation of microbial diversity in theory and in practice. ISME J. 2013;7(6):1092–101. doi: 10.1038/ismej.2013.10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Daniels L, Budding AE, de Korte N, Eck A, Bogaards JA, Stockmann HB, et al. Fecal microbiome analysis as a diagnostic test for diverticulitis. Eur J Clin Microbiol Infect Dis. 2014;33(11):1927–36. doi: 10.1007/s10096-014-2162-3 [DOI] [PubMed] [Google Scholar]
  • 10.Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1792–801. doi: 10.1053/j.gastro.2011.07.043 [DOI] [PubMed] [Google Scholar]
  • 11.Eck A, de Groot EFJ, de Meij TGJ, Welling M, Savelkoul PHM, Budding AE. Robust Microbiota-Based Diagnostics for Inflammatory Bowel Disease. J Clin Microbiol. 2017;55(6):1720–32. doi: 10.1128/JCM.00162-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Danese S, et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol. 2008;42(6):699–703. doi: 10.1097/MCG.0b013e3180653ca2 [DOI] [PubMed] [Google Scholar]
  • 13.Armougom F, Raoult D. Use of pyrosequencing and DNA barcodes to monitor variations in Firmicutes and Bacteroidetes communities in the gut microbiota of obese humans. BMC Genomics. 2008;9:576. doi: 10.1186/1471-2164-9-576 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Dore J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009;9:123. doi: 10.1186/1471-2180-9-123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zullo A, Gatta L, Vassallo R, Francesco V, Manta R, Monica F, et al. Paradigm shift: the Copernican revolution in diverticular disease. Ann Gastroenterol. 2019;32(6):541–53. doi: 10.20524/aog.2019.0410 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Jones RB, Fodor AA, Peery AF, Tsilimigras MCB, Winglee K, McCoy A, et al. An Aberrant Microbiota is not Strongly Associated with Incidental Colonic Diverticulosis. Sci Rep. 2018;8(1):4951. doi: 10.1038/s41598-018-23023-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Tursi A, Mastromarino P, Capobianco D, Elisei W, Miccheli A, Capuani G, et al. Assessment of Fecal Microbiota and Fecal Metabolome in Symptomatic Uncomplicated Diverticular Disease of the Colon. J Clin Gastroenterol. 2016;50Suppl 1:S9–S12. doi: 10.1097/MCG.0000000000000626 [DOI] [PubMed] [Google Scholar]
  • 18.Macchione IG, Lopetuso LR, Ianiro G, Napoli M, Gibiino G, Rizzatti G, et al. Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders. Eur Rev Med Pharmacol Sci. 2019;23(18):8075–83. doi: 10.26355/eurrev_201909_19024 [DOI] [PubMed] [Google Scholar]
  • 19.Jarbrink-Sehgal ME, Rassam L, Jasim A, Walker MM, Talley NJ, Agreus L, et al. Diverticulosis, Symptoms and Colonic Inflammation: A Population-Based Colonoscopy Study. Am J Gastroenterol. 2019;114(3):500–10. doi: 10.14309/ajg.0000000000000113 [DOI] [PubMed] [Google Scholar]
  • 20.Peery AF, Keku TO, Addamo C, McCoy AN, Martin CF, Galanko JA, et al. Colonic Diverticula Are Not Associated With Mucosal Inflammation or Chronic Gastrointestinal Symptoms. Clin Gastroenterol Hepatol. 2018;16(6):884–91 e1. doi: 10.1016/j.cgh.2017.05.051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 2010;5(5):e10667. doi: 10.1371/journal.pone.0010667 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Bian G, Gloor GB, Gong A, Jia C, Zhang W, Hu J, et al. The Gut Microbiota of Healthy Aged Chinese Is Similar to That of the Healthy Young. mSphere. 2017;2(5). doi: 10.1128/mSphere.00327-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lobel L, Cao YG, Fenn K, Glickman JN, Garrett WS. Diet posttranslationally modifies the mouse gut microbial proteome to modulate renal function. Science (New York, NY). 2020;369(6510):1518–24. doi: 10.1126/science.abb3763 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Budding AE, Grasman ME, Eck A, Bogaards JA, Vandenbroucke-Grauls CM, van Bodegraven AA, et al. Rectal swabs for analysis of the intestinal microbiota. PLoS One. 2014;9(7):e101344. doi: 10.1371/journal.pone.0101344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bassis CM, Moore NM, Lolans K, Seekatz AM, Weinstein RA, Young VB, et al. Comparison of stool versus rectal swab samples and storage conditions on bacterial community profiles. BMC Microbiol. 2017;17(1):78. doi: 10.1186/s12866-017-0983-9 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Christopher Staley

20 May 2021

PONE-D-21-08956

Microbiota composition and mucosal immunity in patients with asymptomatic diverticulosis and controls

PLOS ONE

Dear Dr. van Rossen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specific concerns related to patient inclusion criteria and available metadata to contextualize the results are required to explain the novelty and reliability of the current analysis.

Please submit your revised manuscript by Jul 02 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Christopher Staley, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments:

The study addresses an important and emerging question concerning the role of the intestinal microbiota in diverticular disease. As both reviewers acknowledge, age is an important confounding factor, in addition to other exclusion requirements ie, antibiotic exposure or other medications and clinical metadata including immunological assays or dietary surveys are needed to properly contextualize these data. Without these, this is a well conducted survey but provides little novel information.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you are reporting an analysis of a microarray, next-generation sequencing, or deep sequencing data set. PLOS requires that authors comply with field-specific standards for preparation, recording, and deposition of data in repositories appropriate to their field. Please upload these data to a stable, public repository (such as ArrayExpress, Gene Expression Omnibus (GEO), DNA Data Bank of Japan (DDBJ), NCBI GenBank, NCBI Sequence Read Archive, or EMBL Nucleotide Sequence Database (ENA)). In your revised cover letter, please provide the relevant accession numbers that may be used to access these data. For a full list of recommended repositories, see http://journals.plos.org/plosone/s/data-availability#loc-omics or http://journals.plos.org/plosone/s/data-availability#loc-sequencing.

3. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

4. Thank you for stating the following in the Competing Interests section:

"I have read the journal's policy and the authors of this manuscript have the following competing interests: AEB reports personal fees of inBiome B.V. (employee/stock holder)."

We note that one or more of the authors are employed by a commercial company: inBiome B.V..

4.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

4.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

5. Thank you for submitting the above manuscript to PLOS ONE. During our internal evaluation of the manuscript, we found significant text overlap between your submission and the following previously published works, some of which you are an author.

https://research.vu.nl/en/publications/diverticulitis-insights-in-aetiology-and-treatment

We would like to make you aware that copying extracts from previous publications, especially outside the methods section, word-for-word is unacceptable. In addition, the reproduction of text from published reports has implications for the copyright that may apply to the publications.

Please revise the manuscript to rephrase the duplicated text, cite your sources, and provide details as to how the current manuscript advances on previous work. Please note that further consideration is dependent on the submission of a manuscript that addresses these concerns about the overlap in text with published work.

We will carefully review your manuscript upon resubmission, so please ensure that your revision is thorough.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Excellent manuscript showing that the presence of asymptomatic diverticulosis is not associated with significant alterations of intestinal mucosal microbiota. The findings suggest that gut microbiota should not have a major role in the pathogenesis of diverticula. The topic is not completely novel, since there are already some studies investigating the same research question (correctly acknowledged in the discussion). However, the present study has been conducted on a larger sample size and with a sounder methodology than its counterparts.

I have just three comments/suggestions:

1) Cases (patients with diverticulosis) and controls were not matched by age. This is an important limitation of the study. In fact, age is generally considered one of the main determinants of intestinal microbiota composition. However, the effect of age on microbiota begins to be relevant after the age of 70-75 years old, especially is no significant comorbidities or disability exist. Thus, the effect of different age on the microbiota composition of the two groups enrolled in this study could have been negligible, provided that the burden of comorbidities and disability of the two groups was similar. I suggest that the authors include a comment on these issues in their manuscript.

2) No prespecified sample size calculation seems to have been performed for this study. Please specify that the study was conducted on a convenience sample size.

3) It would have been interesting to include in the study also an analysis of the fecal microbiota of participants, to verify whether the composition of the mucosal and fecal microbiota was consistent. Fecal microbiota is much more accessible for analyses, also from a clinical perspective.

Reviewer #2: The topic of this manuscript is very interesting. The pathophysiology of diverticular disease is still incompletely known and the role of microbiota and immunity is only partially reported in the literature. This study evaluated mucosal microbiota and immunity in asymptomatic diverticulosis compared with a control group without diverticula. there are, however, several limitations that make it difficult to support the conclusions speculated by the authors and make the results unreliable. among the exclusion criteria, the authors did not consider the use of antibiotics and laxatives which are factors changing gut microbiota. the lack of information about diet generates doubts about the results. Asymptomatic diverticulosis and controls significantly differ for age, which again influences gut microbiota. without correcting data for this variable, there is likely a bias in the results. Concerning immunity, the study did not look at macrophages, which as authors themselves reported in the manuscript, have been found to be different in diverticular disease compared to controls. all these limitations weaken the results and make it difficult to support the conclusions of the authors.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Sep 7;16(9):e0256657. doi: 10.1371/journal.pone.0256657.r002

Author response to Decision Letter 0


14 Jul 2021

Amsterdam, 02-07-2021

Dear Mr Staley,

Thank you for the review of our manuscript entitled “Microbiota composition and mucosal inflammation in patients with asymptomatic diverticulosis and controls” (PONE-D-21-08956). With these valuable comments we were able to improve our manuscript.

Below I copied the reviewers’ comments and our response to each comment.

We look forward to your response and hope that you find our revised manuscript eligible for publication in PLOS ONE.

Sincerely,

Tess van Rossen

PhD candidate, department of Medical Microbiology & Infection Control, Amsterdam UMC

---------------------------------------------------------------------------------------------------------------------------------

Reviewer comments:

Reviewer #1:

Excellent manuscript showing that the presence of asymptomatic diverticulosis is not associated with significant alterations of intestinal mucosal microbiota. The findings suggest that gut microbiota should not have a major role in the pathogenesis of diverticula. The topic is not completely novel, since there are already some studies investigating the same research question (correctly acknowledged in the discussion). However, the present study has been conducted on a larger sample size and with a sounder methodology than its counterparts.

I have just three comments/suggestions:

1) Cases (patients with diverticulosis) and controls were not matched by age. This is an important limitation of the study. In fact, age is generally considered one of the main determinants of intestinal microbiota composition. However, the effect of age on microbiota begins to be relevant after the age of 70-75 years old, especially if no significant comorbidities or disability exist. Thus, the effect of different age on the microbiota composition of the two groups enrolled in this study could have been negligible, provided that the burden of comorbidities and disability of the two groups was similar. I suggest that the authors include a comment on these issues in their manuscript.

Thank you for the review of our manuscript and for your positive response. We agree that this is a limitation of the study. As you suggested, we included a comment and corresponding references in the discussion section (lines 327-333):

“Our study is hampered by several drawbacks. Firstly, our sample size is small and AD patients and controls were not matched by age. As AD is commonly found with increasing age, our study is not powered to find subtle, age-dependent differences in microbiota composition. Age is generally considered one of the main determinants of intestinal microbiota composition; however this begins to be relevant after the age of 70-75 years old, especially if no significant comorbidities or disability exist (21,22). This is in line with our finding that although the AD group was significantly older than the control group (66 vs 56 years respectively), the microbiota composition did not differ between the two groups.”

In addition, we re-assessed electronic patient records of included patients to evaluate potential differences in comorbidities and disability of the two groups. We found that the burden of disability was similar in the two groups. The results are displayed in Table 1 and included in the Results section (lines 175-179):

“The number of patients with specific comorbidities was similar in the two groups, except that gastro-intestinal disorders and malignancies (but not colon cancer) were more frequent in the control group compared to the AD group. Gastro-intestinal comorbidity in the control group concerned esophagitis (n=2), aspecific colitis (n=1) and irritable bowel syndrome (n=1).”

2) No prespecified sample size calculation seems to have been performed for this study. Please specify that the study was conducted on a convenience sample size.

Thank you for this suggestion, we included this statement in the Methods section (lines 87-88).

3) It would have been interesting to include in the study also an analysis of the fecal microbiota of participants, to verify whether the composition of the mucosal and fecal microbiota was consistent. Fecal microbiota is much more accessible for analyses, also from a clinical perspective.

We agree that an additional analysis of fecal samples (or rectal swabs, also a practical sample type from a clinical perspective) would have been very interesting for comparison between the luminal and fecal microbiota composition. Unfortunately, feces was not collected in this study but we included this suggestion/limitation in the Discussion section (lines 352-356):

“Another option might be to use rectal swabs or feces to verify whether the composition of the mucosal and fecal microbiota was consistent. Furthermore, collection of rectal swabs or feces is more practical and patient-friendly, although these methods have their own disadvantages as described before (24, 25).”

Reviewer #2:

The topic of this manuscript is very interesting. The pathophysiology of diverticular disease is still incompletely known and the role of microbiota and immunity is only partially reported in the literature. This study evaluated mucosal microbiota and immunity in asymptomatic diverticulosis compared with a control group without diverticula. There are, however, several limitations that make it difficult to support the conclusions speculated by the authors and make the results unreliable. Among the exclusion criteria, the authors did not consider the use of antibiotics and laxatives which are factors changing gut microbiota. The lack of information about diet generates doubts about the results.

Thank you for the review of our manuscript your valuable suggestions.

Concerning the exclusion criteria, patients with antibiotics and laxative use were indeed not excluded beforehand. However, we re-assessed electronic patient records of our study population and found that none of the patients received antibiotics, and only few patients used laxatives (AD group: 3 patients, control group: 1 patient). This data is added to the text of the Results section and Table 1 (page 9). Furthermore, all patients underwent routine bowel lavage (high dose laxatives) for colonoscopy so we assume that the potential effect of prior laxative use on the mucosal microbiota composition is probably marginal compared to the effect of the bowel preparation. Unfortunately, data on diet was lacking, since this factor is not regularly reported in patient records. We addressed this limitation in the Discussion section (lines 334-336):

“We only had limited availability to patient demographics. Several other factors such as diet can influence microbiota composition for which should be corrected (23)."

Asymptomatic diverticulosis and controls significantly differ for age, which again influences gut microbiota. Without correcting data for this variable, there is likely a bias in the results.

Thank you for this comment. See also the answer on comment 1 of reviewer #1: We agree that this is a limitation of the study. However, since the microbiota composition of the AD group and control group was comparable despite the difference in age, we do not expect that age has influenced the results. Furthermore, previous studies show that the effect of age on the microbiota composition begins to be relevant after the age of 70-75 years old, while the age of the AD patients and controls was 66 and 56 years old, respectively. Nevertheless, we included this limitation and corresponding references in the discussion section (lines 327-333):

“Our study is hampered by several drawbacks. Firstly, our sample size is small and AD patients and controls were not matched by age. As AD is commonly found with increasing age, our study is not powered to find subtle, age-dependent differences in microbiota composition. Age is generally considered one of the main determinants of intestinal microbiota composition; however this begins to be relevant after the age of 70-75 years old, especially if no significant comorbidities or disability exist (21,22). This is in line with our finding that although the AD group was significantly older than the control group (66 vs 56 years respectively), the microbiota composition did not differ between the two groups.”

Concerning immunity, the study did not look at macrophages, which as authors themselves reported in the manuscript, have been found to be different in diverticular disease compared to controls.

Thank you for this comment. We agree that analysis of macrophages would have been an interesting addition to our study. Unfortunately, this data was not collected in our study set, but we addressed this limitation and suggestion for future studies in the Discussion section (lines 356-358):

“An assessment of other immune cells such as macrophages, or cytokines in our data set could provide a more detailed view of the mucosal immunity in patients with AD and should be evaluated in future studies.”

Additional Editor Comments:

The study addresses an important and emerging question concerning the role of the intestinal microbiota in diverticular disease. As both reviewers acknowledge, age is an important confounding factor, in addition to other exclusion requirements ie, antibiotic exposure or other medications and clinical metadata including immunological assays or dietary surveys are needed to properly contextualize these data. Without these, this is a well conducted survey but provides little novel information.

Thank you for the review of our manuscript and the positive feedback. We agree that the metadata is important for correct interpretation of the results on the role of the intestinal microbiota in diverticulosis and diverticulitis. Therefore, we re-assessed electronic patient records to extract data on potential confounders, such as smoking, alcohol use, antibiotic exposure, and comorbidities. We found no large differences between the two groups. The results are displayed in Table 1 and included in the Results section (lines 173-179):

“Six out of 19 AD patients were smokers, compared to 3/24 controls, and alcohol consumption was slightly higher in the AD group compared to the control group. None of the patients received antibiotics via the hospital prior to colonoscopy. The number of patients with specific comorbidities was similar in the two groups, except that gastro-intestinal disorders and malignancies (but not colon cancer) were more frequent in the control group compared to the AD group. Gastro-intestinal comorbidity in the control group concerned esophagitis (n=2), aspecific colitis (n=1) and irritable bowel syndrome (n=1).”

Attachment

Submitted filename: Response to Reviewers 20210702.docx

Decision Letter 1

Christopher Staley

12 Aug 2021

Microbiota composition and mucosal immunity in patients with asymptomatic diverticulosis and controls

PONE-D-21-08956R1

Dear Dr. van Rossen,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Christopher Staley, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have adequately responded to all my previous comments and correctly acknowledged the study limitations. I have no further concerns.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

Christopher Staley

27 Aug 2021

PONE-D-21-08956R1

Microbiota composition and mucosal immunity in patients with asymptomatic diverticulosis and controls

Dear Dr. van Rossen:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Christopher Staley

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Patient characteristics.

    (XLSX)

    S2 File. Microbiota data.

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers 20210702.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES